Frontlight ResearchEarly access
Not yet taking people in SpainPhase 1/2
Tests HER2-targeted CAR-T cells in adults with advanced HER2-positive breast cancer
Tests ARI-HER2 CAR-T cells in adults with advanced HER2-positive breast cancer.
Key facts
- Who runs it
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
- Where
- Barcelona, Madrid, and Pamplona, SpainSee the 3 sites
- Trial code
- Registry title
- A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 18 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Sept 2030
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced breast cancer that is HER2-positive. It tests ARI-HER2 (HER2BBz CAR-T cells) as a first-in-human treatment.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Advanced breast cancer that is HER2-positive.
- Biomarker or test result
- HER2-positive
Main reasons for not taking part
- Healthy volunteers cannot join.
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Clínica Universidad de navarraPamplona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests HER2-targeted CAR-T cells in adults with advanced HER2-positive breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2026-527365-30-00, who can take part
- Record updated
- 19 October 2026